UBS cuts Albertsons stock price target to $22, maintains neutral rating

Published 16/04/2025, 15:46
UBS cuts Albertsons stock price target to $22, maintains neutral rating

Investors and stakeholders of Albertsons will be watching closely to see how the company’s investments in the coming year will play out against the backdrop of its long-term growth algorithm. The current market positioning of Albertsons, as indicated by UBS’s maintained Neutral rating, suggests a wait-and-see approach as the company navigates through its planned investments and growth initiatives. Analyst targets currently range from $19 to $27, with InvestingPro offering additional insights through its comprehensive Pro Research Report, which provides deeper analysis of the company’s valuation and growth prospects. Analyst targets currently range from $19 to $27, with InvestingPro offering additional insights through its comprehensive Pro Research Report, which provides deeper analysis of the company’s valuation and growth prospects.

Investors and stakeholders of Albertsons will be watching closely to see how the company’s investments in the coming year will play out against the backdrop of its long-term growth algorithm. The current market positioning of Albertsons, as indicated by UBS’s maintained Neutral rating, suggests a wait-and-see approach as the company navigates through its planned investments and growth initiatives. Analyst targets currently range from $19 to $27, with InvestingPro offering additional insights through its comprehensive Pro Research Report, which provides deeper analysis of the company’s valuation and growth prospects.

Carden’s commentary sheds light on the situation, noting that the measures being taken by Albertsons are essential for its continued expansion and the establishment of its media venture. Despite the anticipated decline in EBITDA, these investments are seen as necessary steps for the company’s long-term strategy.

The reduction in the price target reflects the analyst’s assessment of the increased investments and the impact they may have on the company’s financials in the short term. Albertsons’ commitment to growth and productivity enhancements is clear, but the immediate effect on earnings before interest, taxes, depreciation, and amortization (EBITDA) has prompted a more cautious valuation by UBS.

Investors and stakeholders of Albertsons will be watching closely to see how the company’s investments in the coming year will play out against the backdrop of its long-term growth algorithm. The current market positioning of Albertsons, as indicated by UBS’s maintained Neutral rating, suggests a wait-and-see approach as the company navigates through its planned investments and growth initiatives.

In other recent news, Albertsons Companies (NYSE:ACI) reported a robust financial performance for the fourth quarter of 2025, surpassing analyst expectations. The company achieved an adjusted earnings per share (EPS) of $0.46, exceeding the forecasted $0.41, and reported revenue of $18.8 billion, slightly above the anticipated $18.63 billion. Despite these positive results, Albertsons’ stock experienced a decline, reflecting broader market conditions and investor concerns. Additionally, the company saw significant growth in its digital and pharmacy sectors, with digital sales increasing by 24% and pharmacy revenue up by 18%. Albertsons’ strategic investments in technology and product offerings were highlighted as key drivers of this growth. The company’s outlook for fiscal year 2025 includes projections of identical sales growth between 1.5% and 2.5% and an adjusted EBITDA ranging from $3.8 billion to $3.9 billion. Albertsons plans to continue investing in its digital platforms and pharmacy services to drive future growth. Analysts from firms like Goldman Sachs and UBS noted the company’s strategic focus on price investments and digital engagement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.